Weight Loss Drugs Like Ozempic May Pose Surgical Risks

GLP-1 Receptor Agonists Linked to Complications

Patients Advised to Discontinue Use Before Surgery

Patients using popular weight-loss drugs such as Ozempic and Wegovy may face increased surgical risks, according to a new study. These medications, known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have been linked to potential complications before and after surgeries.

GLP-1 RAs stimulate the release of insulin, which helps lower blood sugar and promote weight loss. However, they can also slow gastric emptying, which can lead to stomach problems and other digestive issues. In the case of surgery, this delayed gastric emptying can interfere with anesthesia and increase the risk of aspiration, where stomach contents enter the lungs.

Researchers recommend that patients taking GLP-1 RAs stop taking the medication well in advance of surgery. The specific timing depends on the type of surgery and the individual patient's health status. In some cases, patients may need to discontinue the medication for several weeks or even months before surgery.

Patients should consult with their healthcare providers to determine the appropriate timing for stopping GLP-1 RAs before surgery. It is crucial to follow the doctor's instructions carefully to minimize potential risks.

GLP-1 RAs have been widely used for weight loss and diabetes management. However, the recent study highlights the importance of being aware of their potential surgical risks. Patients should work closely with their healthcare team to make informed decisions and ensure safe and successful surgical outcomes.